In this regard, we initially examined additional breast cancer therapy response cohorts, focusing on Pathological Complete Response (pCR, n=1775) and 5-year Relapse-Free Survival (RFS, n=1329) to assess the associations between Siglec-7 gene expression and response status to conventional treatments, including endocrine therapy (hormonotherapy), anti-HER2 therapy, and chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.